Build to sell, or build to run: a strategic choice for medical device founders.

i. The decision most founders make by default

Ask a typical medical device founder at the start of their journey: "Are you building this company to sell or to commercialize?"

A few will have a crisp answer. Most will say something like "Well, we’re going to commercialize, but if a great offer came along..." or "We’re keeping options open" or "It depends on traction."

Those answers feel reasonable. They’re also expensive.

The problem isn’t that the founder hasn’t decided — it’s that the absence of an explicit decision is itself a decision. Without a clear answer, every operational choice defaults toward commercialization mode: hire full-time QA, buy the enterprise eQMS, build the customer support function, raise the bigger round, lease the office. These choices feel like "doing it right." They’re also exactly what a sale-track company would deliberately avoid.

By the time most founders realize this — usually around Series A or B, when burn rate exceeds runway projections — they’ve already committed millions of dollars and 18–24 months of organizational habit to commercialization infrastructure. Walking it back is hard. Selling a company that’s been built for commercialization is also harder than selling a company that was deliberately built as a clean acquisition target.

The point of this article isn’t to argue that selling is better than commercializing. Both are legitimate paths and both have created enormous value. The point is that the choice should be made on purpose, early enough to matter, and revisited deliberately at each funding milestone.

ii. Two companies, one product

To understand why the decision matters, imagine two medical device startups with identical products — same hardware, same software, same intended use, same Class II classification, same 510(k) pathway. Call them Company A and Company B.

Company A is built to sell. The founders have looked at acquisition activity in their device category, identified five potential strategic acquirers, and structured the company to be an attractive bolt-on. Their goal is FDA clearance plus a deliverable asset package, then a sale conversation. They expect to exit within 6–18 months of clearance.

Company B is built to commercialize. The founders intend to bring the device to market themselves, build a sales organization, manufacture at scale, and operate the device as a business for years. They may eventually sell, but only after demonstrating commercial traction.

Despite identical products and identical regulatory pathways, these two companies look almost nothing alike. Their QMS scope differs, their headcount differs, their tooling differs, their capital structure differs, their risk profile differs, their executive priorities differ, and the founders’ day-to-day experience differs.

Most founders never explicitly compare these two versions of their own company. They build something that’s neither — too lean to commercialize effectively, too cluttered to be a clean acquisition target — and pay a hidden cost for that ambiguity throughout the company’s life.

iii. Sale-track: company as regulatory asset

When a company is built to sell, its purpose becomes producing one valuable, transferable thing: a clean regulatory submission package and an FDA clearance letter, along with the design history, technical documentation, and intellectual property that supports it.

Everything else is overhead. The discipline of sale-track is recognizing that overhead as overhead.

QMS scope

Built narrowly around design controls and the SOPs that directly support the submission. Core procedures include design controls, document control, supplier controls (for the components that go into the design), risk management (ISO 14971), software development lifecycle (IEC 62304 if applicable), and management responsibility. Procedures for full commercial operations — complaint handling at scale, manufacturing process validation, post-market surveillance programs, advanced CAPA workflows — exist but are minimal, designed to satisfy the submission rather than to actually run a business.

eQMS tooling

Lean and inexpensive. A focused eQMS platform suitable for sale-track companies typically runs $300–$800 per month (estimates only — pricing varies by vendor, modules, and user count). Some companies even operate effectively on well-organized cloud document repositories with controlled access during the design phase, transitioning to a formal eQMS only when needed for the submission. The decision criteria is: does this tool support the submission? If yes, lightweight is fine. There’s no point investing in modules for manufacturing operations the company will never perform.

Headcount

Minimal. The typical sale-track team:

• CEO (full-time)
• CTO (full-time)
• Hardware/software engineering (full-time, 2–6 people depending on complexity)
• Fractional QA (typically a senior consultant or part-time QA Manager)
• Fractional RA (consulting basis, scaling up around submission preparation)
• Fractional finance (bookkeeper plus a fractional CFO)
• Fractional legal (outside counsel for IP, contracts, regulatory)

Total: typically 5–8 FTEs at the time of submission. No sales, no marketing, no operations, no manufacturing staff, no customer support, no full-time HR.

Capital required

Roughly $2–5M to clearance for a focused SaMD or simpler device, $5–10M for moderate-complexity devices (estimates only — actual requirements vary significantly with device complexity, clinical data requirements, and team geography). The capital efficiency of sale-track is one of its defining advantages. Less dilution, less time chasing investors, less pressure to grow before the company is ready.

Timeline

Often 18–30 months from incorporation to a clearance letter, then 6–18 months to close a sale. Total: typically 2–4 years to exit, though this varies widely.

Executive focus

The CEO’s job is regulatory milestone management plus acquirer cultivation. By the time the clearance arrives, the strategic conversations should already be in progress. Sale-track CEOs spend significant time at industry events, in conversations with corporate development teams at potential acquirers, and managing the data room.

iv. Commercialize-track: company as ongoing business

When the goal is commercialization, the company has to be built to operate the device as a real business — manufacturing, distributing, supporting, billing, and continuously improving the product over years.

This is where most founders dramatically underestimate complexity. The 510(k) clearance is not the finish line. It’s the starting line of a much longer race.

QMS scope

Full. Has to handle every requirement that applies to a commercial medical device manufacturer. Beyond what sale-track companies need, this includes:

• Complaint handling and trending (volume increases dramatically post-launch)
• Medical Device Reporting (MDR) decision-making and submission
• Post-market surveillance programs (active, not just procedural)
• Manufacturing process validation and ongoing process monitoring
• Supplier controls at production scale (not just design)
• Distribution controls and traceability
• Production change controls
• Advanced CAPA workflows with real volume
• Training programs for production and support staff
• Internal audit programs scoped to ongoing operations

eQMS tooling

More substantial. A commercialization-track eQMS typically runs $2,000–$5,000 per month for a small-to-mid-size company (again, estimates only — significant variation by vendor and modules). The tool has to actually operate the business: track complaints, manage MDR decisions, control production documents, route CAPAs, support audit trails for FDA inspections, and integrate with manufacturing systems. Underspending here creates operational pain that compounds.

Headcount

Substantial and growing. The typical commercialization-track team at launch:

• CEO, CTO (full-time)
• Hardware/software engineering (full-time, often 6–12 people)
• Full-time QA Manager (this is non-negotiable — commercializing companies cannot run on fractional QA leadership)
• Full-time Regulatory Affairs Manager
• Operations (manufacturing oversight, supply chain, fulfillment)
• Customer support team (2–5 to start, growing with installed base)
• Sales team (varies enormously by go-to-market model)
• Marketing (product marketing, content, demand generation)
• Finance (bookkeeper, controller, often a CFO)
• HR (initially fractional, becomes full-time around 30–50 employees)
• IT (systems administration, security)

Total: typically 25–50+ FTEs by the time the product is generating meaningful revenue, depending on device category and go-to-market model. For some categories — implantables, surgical devices, complex hospital sales — even this is conservative.

Capital required

Substantially higher. $15–30M+ to launch and reach commercial viability is a reasonable estimate for many categories, with hardware-intensive or sales-heavy categories pushing well above that (these are estimates only and vary enormously by device type, go-to-market model, and geography). The capital isn’t just for the launch — it’s for the operating cash burn through customer acquisition, sales cycle length, and the inevitable scaling challenges.

Timeline

Indefinite. Commercialization is an ongoing operating posture, not a milestone. Successful commercialization-track companies are still operating decades later.

Executive focus

Dramatically different. The CEO is running a real company — customer escalations, sales pipeline, fundraising rounds, hiring, board management, manufacturing crises, partner negotiations. The regulatory work is one stream among many, often not the bottleneck.

v. The full comparison

Dimension	Sale-Track	Commercialize-Track
End goal	FDA clearance + acquisition	Operate device as ongoing business
QMS scope	Design controls + submission support	Full lifecycle including manufacturing, complaints, MDR, PMS
Core SOPs	Design controls, risk, document control, supplier (design), SDLC	All of sale-track plus: manufacturing, complaint handling, MDR, distribution, training
eQMS tooling	Lean ($300–$800/month*)	Substantial ($2,000–$5,000/month*)
Full-time headcount	5–8 FTEs	25–50+ FTEs
Fractional roles	QA, RA, finance, legal, HR	Eventually replaced with full-time hires
Capital needed to milestone	$2–5M to clearance*	$15–30M+ to commercial viability*
CEO role	Regulatory milestones + acquirer cultivation	Operating a multi-function business
Manufacturing	CMO-managed if needed for testing	Full CMO relationship + internal oversight
Customer support	None	Full team, training, systems
Sales & marketing	None	Full function
Risk profile	Regulatory submission risk	Submission risk + recall risk + inspection risk + commercial risk
Timeline to liquidity	2–4 years	Indefinite (or 7–10+ years to acquisition/IPO)
Optionality	Can pivot to commercialize later if no buyer	Difficult to "right-size" back to sale-track

*All cost estimates are illustrative and vary significantly by device complexity, geography, and specific operational choices. Actual numbers should be modeled for your specific situation.

The asymmetry of the bottom row is worth dwelling on. A sale-track company that doesn’t get acquired can almost always pivot to commercialization — you’ve under-built, and you need to add capability. That’s a manageable problem given enough capital. A commercialization-track company that fails to commercialize cannot easily become an attractive acquisition target — you’ve over-built, and you’ve burned the capital that would have made a clean sale-track exit appealing. Acquirers don’t pay extra for a customer support team they’re going to dissolve.

This asymmetry is the reason for the subtle bias in this article. If you’re genuinely uncertain about your end goal, sale-track preserves more optionality.

vi. Capital implications

The capital implications of this decision compound in ways that are not always obvious.

Dilution. A company that raises $4M to clearance and exits for $40M has very different founder economics than a company that raises $25M to commercialize and exits for $100M. Run the math on your own situation — the higher exit price doesn’t automatically mean better founder outcomes after dilution.

Round timing. Sale-track companies typically raise one or two rounds before exit (seed + Series A, or seed + Series A + a bridge). Commercialization-track companies typically raise four to six rounds (seed, A, B, C, often more). Each round costs 3–6 months of CEO time and meaningful dilution.

Investor expectations. Sale-track companies set expectations with investors from the beginning that an early exit is the plan. Commercialization-track companies set expectations that they’re building for the long term. Mismatches between founder intent and investor expectations are a primary cause of board-level conflict. Decide early so you can pick investors who want what you want.

Runway during regulatory work. Both paths involve a long stretch of expensive regulatory work before revenue. Sale-track companies size their runway to cover regulatory milestones plus a sale conversation buffer. Commercialization-track companies size for regulatory milestones plus the first 12–18 months of post-launch burn before unit economics work. The runway requirements look very different.

vii. The risks founders underestimate

Most founders who choose commercialization without fully understanding the consequences are surprised by specific categories of risk that aren’t visible at the founding stage.

Recall risk

Once a product is on the market, a recall can be a company-ending event. The financial cost is meaningful; the reputational cost can be larger. Sale-track companies don’t carry this risk — if there’s a defect, it’s the acquirer’s problem post-close. Commercialization-track companies live with this risk daily for the life of the product.

FDA inspection risk

Manufacturing facilities (including CMO sites) are subject to FDA inspection, and the operating QMS will be examined. A poor inspection outcome (Form 483 observations, Warning Letters, consent decrees) can stop production, affect existing contracts, and require expensive remediation. Sale-track companies are often acquired before this becomes a serious concern. Commercialization-track companies have to operate inspection-ready continuously.

Contract manufacturer complexity

Most founders dramatically underestimate the day-to-day complexity of managing a CMO relationship at commercial scale. Quality agreements, change controls, supplier audits, scorecards, escalations, capacity planning, multi-source strategies, technology transfer, and continuous improvement programs all become real work. Companies usually need a dedicated supplier management function by the time they’re shipping product at scale.

Customer support complexity

Medical devices require trained customer support. Complaints have regulatory implications (MDR decisions). Training programs need ongoing maintenance. Field service may be required. Customer-facing staff need device-specific knowledge that takes months to develop. This function is invisible in pitch decks but consumes significant founder attention post-launch.

Operating systems sprawl

Commercialization requires HR systems, finance/accounting systems, billing systems, refund processing, customer relationship management, marketing automation, IT security, business continuity planning, and integration between all of these. None of this exists at the founding stage. All of it has to be built or bought, integrated, and maintained.

The point of this list isn’t to scare founders away from commercialization. Many medical device companies have commercialized successfully and built durable, valuable businesses. The point is that the operational complexity of commercialization is invisible from the founding-stage vantage point, and founders should understand it before committing.

viii. When to make the decision (and when to revisit it)

The cleanest time to make this decision is at incorporation, before the first round of capital. This is when:

• Investor selection can be matched to intent
• The cap table can be structured for the planned exit profile
• The team can be assembled with the right mix of full-time and fractional
• The QMS architecture can be scoped from day one
• Capital plans can be sized correctly

The next-cleanest times are at each subsequent funding milestone. A founder who chose sale-track at seed should explicitly ask, when considering a Series A: "Are we still sale-track, or has something changed that makes commercialization the better path?" Similarly for commercialization-track companies — at each round, the question "is the path still right?" should be on the table.

The hardest time to revisit the decision is after operational infrastructure has been built around the wrong choice. A commercialization-track company three years into building its sales organization cannot easily become sale-track. A sale-track company nine months from clearance with no commercial infrastructure cannot easily switch to commercialization without a major capital event. The cost of changing course rises sharply once organizational habits and infrastructure are in place.

A reasonable cadence: make the decision at incorporation, revisit it at every funding milestone, revisit it any time a major operational decision is on the table (a key hire, a tool purchase, a significant capital commitment). Treat it as a living strategic choice, not a one-time question.

ix. Practical guidance for founders

If this article has surfaced uncertainty about your own company’s direction, here are concrete next steps:

1. Have the conversation explicitly. With your co-founders, your board, and your closest advisors. Write down the answer. Date it.
2. Map your current operational state against both columns. Are you building a sale-track company by your actions, or a commercialization-track company? Mismatches between intent and action are the most expensive form of strategic drift.
3. Identify your top 3–5 potential acquirers — even if you intend to commercialize. Knowing who would buy your company tells you a lot about what makes the company valuable, what they care about in due diligence, and what infrastructure you do and don’t need to build.
4. Pressure-test your capital plan against your end goal. If you’ve raised $10M with a plan to clear FDA and sell, but your operating burn implies a $30M commercialization plan, there’s a gap that needs to be closed — either in fundraising plans or operational scope.
5. Build the QMS to your intent, not to a maximalist template. A sale-track company doesn’t need every SOP that a textbook QMS includes. A commercialization-track company needs SOPs that some templates omit. Either way, scope the QMS to the actual operating model. (See our guide to medical device regulatory strategy for more on aligning regulatory work with business goals.)
6. Hire (and don’t hire) accordingly. The single most consequential operational consequence of this decision is who you hire full-time. Resist the urge to "play company" by hiring titles you don’t yet need. Resist the urge to permanently defer hires you’ll regret deferring once commercialization is underway.
7. Make peace with the path you choose. Both paths have created enormous value. Both have produced founders who feel proud of what they built. The worst outcome is choosing neither deliberately and ending up with a company that wasn’t right for either.

x. Common questions

Can a company start as sale-track and pivot to commercialization?

Yes — and this is the most common direction of change. A company built lean for a regulatory milestone can add commercial infrastructure if a sale doesn’t materialize or if an unexpectedly strong market opportunity appears. The reverse is much harder.

Can a commercialize-track company sell mid-journey?

Yes, but typically at a discount to what a clean sale-track exit would have produced. Acquirers usually value the product, the IP, and the FDA clearance — not the redundant infrastructure (sales team, support, marketing) that they already have. Companies that commercialized partway and then sold often saw their organizational investment underappreciated in valuation.

What if my investors push for commercialization when I want to sell?

This is a real conflict and worth surfacing before it becomes a board-level dispute. Some investors only make returns on commercialization-scale exits ($500M+ outcomes). Others are happy with clean $50M–$200M sale-track exits. Knowing your investors’ return expectations before you take their capital is essential. Mismatched expectations are a primary cause of post-Series A founder/investor conflict.

How do I know which path is right for my specific situation?

There’s no universal answer, but useful questions include: How crowded is the competitive landscape for your device category? Are there clear strategic acquirers actively buying in your space? What’s your personal appetite for building and running an operating company versus building and exiting? What does your capital access realistically look like? How sensitive is your market window to speed? A 60-minute conversation with someone who’s been on both sides of these decisions usually clarifies more than reading any article can.

Does the FDA QMSR transition (effective February 2026) change anything about this?

Not fundamentally. The QMSR aligns FDA’s quality system requirements with ISO 13485:2016, which simplifies global expansion but doesn’t change the underlying sale-track vs. commercialize-track choice. If anything, the harmonization makes sale-track slightly more attractive for companies whose acquirers may be international — the QMS is more directly transferable.

Do I need a different consultant for sale-track versus commercialize-track work?

No, but you should choose a consultant who understands both models and can scope your QMS, your regulatory work, and your fractional staffing to your specific intent. Generic "we’ll build you a textbook QMS" consulting often produces a QMS that’s too heavy for sale-track companies and not quite right for commercialize-track companies either.

What about going public (IPO) instead of being acquired?

IPO is a form of commercialization, not an alternative to it. Public companies are operating companies by definition. The IPO event is a liquidity milestone, but the company has to continue operating as a real business afterward — typically with even more rigorous quality, regulatory, and reporting requirements than a private commercializing company. The choice between sale and commercialization remains the same; IPO just changes when and how the commercialization gets capitalized.

Closing

The most expensive medical device companies aren’t the ones that chose the wrong path. They’re the ones that didn’t choose at all — and ended up building infrastructure for both, optimized for neither, and carrying the cost of that ambiguity throughout the company’s life.

Choose deliberately. Revisit often. Build the company that matches your choice.